Antibody-drug conjugates (ADCs) combine the targeting precision of monoclonal antibodies with the potency of cytotoxic drugs, making them one of the most promising therapeutic classes in oncology and beyond. Due to their complexity, working with specialized ADC CDMO companies is essential to navigate the technical, regulatory, and manufacturing challenges unique to these biologics.
From conjugation chemistry to payload handling, antibody-drug conjugate contract manufacturing requires expertise across biologics, small molecules, and high-potency containment — all within a tightly controlled GMP framework.